View clinical trials related to Dengue Hemorrhagic Fever.
Filter by:To evaluate effect of previous flavivirus exposure on the safety and immunogenicity of the ChimeriVax™ dengue tetravalent vaccine Primary Objectives: - To describe the safety of one injection of ChimeriVax™ dengue tetravalent vaccine. - To describe the immune response against dengue before and after one injection of ChimeriVax™ dengue tetravalent vaccine
This study used 3 different formulations of tetravalent CYD dengue vaccine. The primary objective of the study was to evaluate the neutralizing antibody response after 2 doses of two different formulations of tetravalent dengue vaccine administered at Month 0 and Month 6. The secondary objectives were: - To evaluate the safety of the 3 formulations of tetravalent CYD dengue vaccine. - To describe the neutralizing antibody responses to each of the 3 vaccine formulations. - To describe vaccine viremia after the first and second dose of each of the 3 vaccine formulations in a subset of participants.
The purpose of this study is to evaluate the safety and effectiveness of two different formulations of an investigational dengue vaccine (T-DEN) against a placebo vaccine when two doses are given six months apart to adults and children.
Dengue fever, which is caused by dengue viruses, is a major health problem in subtropical regions of the world. There are four different forms (serotypes) of dengue virus that can cause dengue fever. The purpose of this study is to determine the safety and immune response to a vaccine containing a particular dengue serotype when an individual has been previously vaccinated with a different dengue serotype.